Draft Guidance on Clobazam

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Clobazam

Form/Route: Suspension/Oral

Recommended studies: 2 studies

1. Type of study: Fasting  
   Design: Single-dose, two-way crossover in vivo  
   Strength: 2.5 mg/mL (A dose of 20 mg clobazam, i.e. 8 mL suspension is suggested)  
   Subjects: Healthy males and nonpregnant females, general population.  
   Additional Comments: Please refer to the Amiodarone Hydrochloride Tablet Draft Guidance for additional information regarding long half-life drug studies.

2. Type of study: Fed  
   Design: Single-dose, two-way crossover in vivo  
   Strength: 2.5 mg/mL (A dose of 20 mg clobazam, i.e. 8 mL suspension is suggested)  
   Subjects: Healthy males and nonpregnant females, general population.  
   Additional Comments: Please see comments above. Please refer to Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analytes to measure (in appropriate biological fluid): Clobazam and its active metabolite, N-desmethylclobazam, in plasma

Bioequivalence based on (90% CI): Clobazam

Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Waiver request of in vivo testing: Not Applicable
Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products.Specifications will be determined upon review of the application.